Ziphius is a preclinical biotech company specializing in vaccines and therapeutic drugs for infectious diseases, protein replacement therapies, and oncology. Founded in 2019, Ziphius has been advancing its self-amplifying RNA (saRNA) and Lipid Nanoparticle (LNP) platforms. The saRNA technology boasts self-replicating properties, leading to higher protein expression at lower doses, offering advantages over traditional and non-replicating mRNA technologies. These include a broad immune response, sustained protein expression, low toxicity, and flexible production processes. Ziphius has also developed a proprietary LNP library for saRNA delivery. These carriers ensure effective encapsulation, stability, and biodegradability, optimized for targeting specific organs and tissues, thereby minimizing toxicity and maximizing the efficacy of vaccinations and gene therapies. The Ziphius team comprises 61 dedicated researchers and staff, with locations in Merelbeke, Belgium, and New York, USA.